CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma	80
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel	48
Issue Information	43
Issue Information	40
Development and application of a pediatric mechanistic kidney model	36
Toward Precision Dosing of Lamotrigine During Pregnancy: Physiologically Based Pharmacokinetic Modeling and Simulation	35
Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action	35
Tumor growth inhibition modeling to support the starting dose for dacomitinib	34
Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids	34
Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	30
gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve	30
Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients	26
Issue Information	26
Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform	25
	24
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	24
	23
PBPK‐Led Assessment of Antimalarial Drug Concentrations in Breastmilk: A Strategy for Optimal Use of Prediction Methods to Guide Decision Making in an Understudied Population	23
Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients	23
LaTeX tutorial for the standardization and automation of population analysis reports	22
Issue Information	22
Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling	21
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	20
The Asian Pharmacometrics Network: The historical background, establishment, objectives and roles, and recent activities	20
Estimating fetal exposure to the P‐gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome	19

Perspectives on training quantitative systems pharmacologists	19
	19
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	18
A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer	18
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	17
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development	17
Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania	17
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab	17
	17
Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy	16
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	16
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	16
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis	16
Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis	16
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	15
PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris	15
PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria	15
	15
Issue Information	15
Issue Information	15
A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials	15
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	14
	14
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients	14
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	14
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	14
Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology	14
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	14
	13
Enhanced Sensitivity to Tramadol in Diabetic Neuropathic Pain Compared to Nerve Compression Neuropathies: A Population PK/PD Model Analysis	13
Pharmacometric and statistical considerations for dose optimization	13
	13
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	13
Exploration of the potential impact of batch‐to‐batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products	13
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study	13
Issue Information	13
Evaluation of covariate effects in item response theory models	12
Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy	12
Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item‐score models	12
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	12
Issue Information	12
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	12
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor	12
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	11
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	11
Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19	11
Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma	11
Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug–drug interactions	11
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	11
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	11

Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment	11
WITHDRAWAL: Quantitative modeling of approved and emerging therapeutics for modifying TTR levels in patients with Transthyretin Amyloid Cardiomyopathy	11
Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making	11
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy	11
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	11
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients	11
Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children	11
Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling	11
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women	10
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	10
Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox	10
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	10
Correction to “Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution”	10
Issue Information	10
SAMBA: A novel method for fast automatic model building in nonlinear mixed‐effects models	10
Correction to: Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first‐line gastric cancer and elevated plasma VEGF‐A	10
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs	10
Network module‐based drug repositioning for pulmonary arterial hypertension	10
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	10
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics	10
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	10
Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model	9
Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass	9
A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody	9
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization	9
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	9
Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab	9
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	9
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	9
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	9
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	9
Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions	9
Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibo	8
Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib	8
Issue Information	8
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	8
Hallmarks of neurodegenerative disease: A systems pharmacology perspective	8
End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor	8
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report	8
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr	8
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	8
Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria	8
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	8
	8
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	8
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	8
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	8
Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid	8
A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease	8
Efficient and relevant stepwise covariate model building for pharmacometrics	8
Response to ‘Modeling is data driven: Use it for successful virtual patient generation’	8
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	8
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	8
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	8
Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder	8
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models	8
Altered intravenous drug disposition in people living with cystic fibrosis: A meta‐analysis integrating top‐down and bottom‐up data	8
Comparing Scientific Machine Learning With Population Pharmacokinetic and Classical Machine Learning Approaches for Prediction of Drug Concentrations	8
Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents	7
A bootstrapping method to optimize go/no‐go decisions from single‐arm, signal‐finding studies in oncology	7
Issue Information	7
Pyridoxic Acid as Endogenous Biomarker of Renal Organic Anion Transporter Activity: Population Variability and Mechanistic Modeling to Predict Drug–Drug Interactions	7
Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals	7
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	7
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression	7
Can a propensity score matching method be applied to assessing efficacy from single‐arm proof‐of‐concept trials in oncology?	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation	7
Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network	7
Mechanistic modeling of drug products applied to the skin: A workshop summary report	7
Response to “mixed‐effects models and the drug titration paradox”	7
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic	7
Cluster Gauss‐Newton method for a quick approximation of profile likelihood: With application to physiologically‐based pharmacokinetic models	7
A multistate platform model for time‐to‐event endpoints in oncology clinical trials	7
Reproducing prolonged time to peak bisoprolol concentration by PBPK modeling with lysosomal trapping in enterocytes	7
Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia	7
Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies	7
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	7
Cell‐level systems biology model to study inflammatory bowel diseases and their treatment options	7
Issue Information	7

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study	7
Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid ca	7
Data‐driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment	7
Perspective on model‐informed drug development	6
Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate	6
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	6
Nonparametric goodness‐of‐fit testing for parametric covariate models in pharmacometric analyses	6
Is PBPK useful to inform product label on managing clinically significant drug interactions mediated by cytokine release syndrome?	6
Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma	6
Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm	6
Issue Information	6
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	6
Issue Information	6
Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers	6
Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer	6
A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria	6
Enhancing inclusivity in clinical trials: Model‐informed drug development for pregnant individuals in the era of personalized medicine	6
	6
Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer	6
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors	6
N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner—A pharmacokinetic/pharmacodynamic analysis	6
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	6
Pharmacometrics in obstetrics and maternal–fetal medicine research: Bridging gaps in maternal and fetal pharmacology	6
Pharmacokinetic modeling of morphine and its glucuronides: Comparison of nebulization versus intravenous route in healthy volunteers	6
Issue Information	6
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions	6
	6
Issue Information	6
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	6
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	6
Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine	6
Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	6
Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions	6
Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy	6
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	5
Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates	5
Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients	5
	5
Exposure‐response modeling for extrapolation from adult to pediatric patients who differ with respect to prognostic factors: Application to everolimus	5
Abstracts	5
Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia	5
Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab	5
A physiologically‐based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites	5
Issue Information	5
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Car	5
Building an adaptive dose simulation framework to aid dose and schedule selection	5
Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator	5
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide	5
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients	5
Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model‐informed drug development case study	5
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	5
Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma	5
Comprehensive Parent‐Metabolite PBPK/PD Modeling Insights Into Methotrexate Personalized Dosing Strategies in Patients With Rheumatoid Arthritis	5
Investigation of simplified physiologically‐based pharmacokinetic models in rat and human	5
US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer	5
Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients	5
Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias	5
Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies	5
Delineating gene–environment effects using virtual twins of patients treated with clozapine	5
	5